Treatment for Bile Duct Cancer in the Liver

Inclusion Criteria: * Age\>18 years * Histological or cytological diagnosis of cholangiocarcinoma * Disease not amenable to surgery * Predominant disease load in the liver (in case of extra-hepatic involvement, only patients with lymph nodes metastases are allowed) * Naïve to locoregional or systemic treatment (but patients who develop recurrent disease after surgery are suitable) * ECOG PS 0-1 * At least one measurable disease lesion according to RECIST v 1.1 * Life expectancy of 12 weeks or longer * Adequate hematological, renal and hepatic function * Platelet ≥100 x 109 * ANC ≥ 1.5 x 109 * Bilirubin ≤ 30µmol/L * Albumin ≥ 30g/L * ALT ≤ 3 ULN * INR ≤ 1.5 * Serum creatinine ≤ 1.5 x ULN Exclusion Criteria: * Prior malignancy except cervical carcinoma-in-situ or treated basal cell carcinoma. Any cancers treated curatively \> 5 years prior to study entry are permitted. * Patients with extra-hepatic disease other than regional lymph node metastases. * Evidence of ascites or cirrhosis, as determined by clinical or radiologic assessment * Biliary obstruction with no possibility of drainage * Non-malignant disease that would render the patient unsuitable for treatment according to the protocol * Prior treatment of chemotherapy for the cholangiocarcinoma * Prior radiation therapy to the upper abdomen * Complete thrombosis of the main portal vein * Tumor volume \> 50% of the normal liver volume * Allergy to non-ionic contrast agents